
Dr. Gumbleton's primary practice pearl for the management of patients with EGFR-mutated NSCLC in 2026: with very few exceptions, every treatment-naïve patient deserves frontline combination therapy.

Dr. Gumbleton's primary practice pearl for the management of patients with EGFR-mutated NSCLC in 2026: with very few exceptions, every treatment-naïve patient deserves frontline combination therapy.

Dr. Riess presents a 55-year-old male former light smoker with stage IV EGFR L858R adenocarcinoma, ECOG performance status 1, three small asymptomatic brain metastases (largest 8 mm) on baseline brain MRI, no TP53 or other high-risk co-mutation, employed as a remote software engineer with concern about preserving cognitive function and work capacity.

Dr. Riess presents a 52-year-old never-smoking woman with stage IV EGFR exon 19 deletion non-small cell lung cancer, performance status 0, full-time employment as a teacher, no significant comorbidities, and no baseline CNS metastases on brain MRI.

Dr. Riess addresses dose modification frequency in MARIPOSA: dose interruptions in 83% of patients, dose reductions in 59%, and any-agent discontinuation in 35%, with only 10% discontinuing all agents due to treatment-related adverse events.

Dr. Gumbleton discusses how proactive dermatologic management translates into day-to-day clinical practice for patients receiving amivantamab-lazertinib for EGFR-mutated NSCLC.

Dr. Riess presents the COCOON trial data, which evaluated a standardized prophylactic regimen for dermatologic adverse event management with amivantamab-lazertinib in patients with EGFR-mutated NSCLC.

Dr. Gumbleton explains the mechanism of action of amivantamab-lazertinib for clinicians treating patients with EGFR-mutated NSCLC.

Dr. Riess addresses the high rate of CNS metastasis development in EGFR-mutated NSCLC (25%-45%), noting that MARIPOSA's requirement for serial brain MRIs in all participants generated robust intracranial efficacy data.

Dr. Riess highlights TP53 co-mutation as one of the most compelling high-risk subgroups in EGFR-mutated NSCLC, asking Dr. Fidler how TP53 co-mutation status influences frontline treatment selection.

Dr. Jonathan Riess introduces the program on first-line treatment strategies in EGFR-mutated NSCLC, joined by Dr. Mary Jo Fidler and Dr. Matthew Gumbleton.

Jonathan Wesley Riess, MD, MS, discusses the evolving landscape of KRAS inhibitors, including the distinction between KRAS(OFF) and (ON) inhibitors.

Jonathan Riess, MD, MS, and Nicholas Villanueva, MD, discuss the future of personalized treatment in EGFR-mutant NSCLC.

Jonathan Riess, MD, MS, and Nicholas Villanueva, MD, discuss how antibody-drug conjugates are shaping treatment strategies after progression.

Jonathan Riess, MD, MS, and Nicholas Villanueva, MD, discuss treatment sequencing following progression on intensified regimens.

Jonathan Riess, MD, MS, and Nicholas Villanueva, MD, outline the role of ctDNA in guiding treatment decisions.

Jonathan Riess, MD, MS, and Nicholas Villanueva, MD, examine how high-risk disease is defined and applied in clinical practice.

Jonathan Riess, MD, MS, and Nicholas Villanueva, MD, examine how overall survival data from recent trials are influencing treatment decisions.

Jonathan Riess, MD, MS, and Nicholas Villanueva, MD, discuss key inflection points in frontline treatment of EGFR-mutant NSCLC.

Experts discuss the evolving landscape of HER2-targeted therapies in non-small cell lung cancer, emphasizing the need for more data and innovative treatments.

Experts discuss the evolving treatment landscape for HER2-mutated non-small cell lung cancer, focusing on trastuzumab deruxtecan and zonertinib efficacy.

Explore the latest strategies in treating HER2-mutated non-small cell lung cancer with antibody-drug conjugates and targeted therapies.

Explore the latest insights on sevobertnib and zonertinib in treating HER2-mutated non-small-cell lung cancer, focusing on efficacy and toxicity differences.

Explore the latest insights on sevobertnib and zonertinib in treating HER2-mutated non-small-cell lung cancer, focusing on efficacy and toxicity differences.

Explore the latest advancements in HER2 testing and treatment strategies for non-small cell lung cancer, enhancing patient outcomes and options.

Explore the latest advancements in HER2 testing and treatment strategies for non-small cell lung cancer in this insightful discussion.

Experts discuss the importance of HER2 IHC testing and tissue management in cancer treatment, emphasizing its role in personalized therapy.

Experts discuss the latest advancements in HER2 testing and treatment strategies for non-small cell lung cancer, enhancing clinical practice and patient outcomes.

Panelists discuss how novel agents and emerging strategies may further optimize sequencing and outcomes for EGFR PACC-mutated NSCLC.

Panelists discuss how the FURTHER trial demonstrated firmonertinib’s efficacy and safety in patients with PACC mutations.

Panelists discuss how firmonertinib shows promise as a next-generation TKI with broad EGFR activity and favorable tolerability.

April 13th 2026

March 30th 2026

April 6th 2026

December 3rd 2024